Browsing Tag

CA9

ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment

Eli Pacheco Mar 8, 2022 0

MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,…

Health

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Eli Pacheco Dec 21, 2021 0

MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today…

Health

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Eli Pacheco Oct 5, 2021 0

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been…